Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Operating Expenses (2024 - 2026)

Prelude Therapeutics' Operating Expenses history spans 3 years, with the latest figure at $18.8 million for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 45.8% to $18.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $100.9 million, a 31.38% decrease, with the full-year FY2025 number at $116.7 million, down 20.45% from a year prior.
  • Operating Expenses hit $18.8 million in Q1 2026 for Prelude Therapeutics, down from $23.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for PRLD hit a ceiling of $37.8 million in Q4 2024 and a floor of $18.8 million in Q1 2026.
  • Historically, Operating Expenses has averaged $31.4 million across 3 years, with a median of $34.3 million in 2024.
  • Biggest five-year swings in Operating Expenses: increased 0.77% in 2025 and later plummeted 45.8% in 2026.
  • Tracing PRLD's Operating Expenses over 3 years: stood at $37.8 million in 2024, then crashed by 39.24% to $23.0 million in 2025, then dropped by 18.41% to $18.8 million in 2026.
  • Business Quant data shows Operating Expenses for PRLD at $18.8 million in Q1 2026, $23.0 million in Q4 2025, and $26.9 million in Q3 2025.